WATCH: Interviews from 30th European Haematology Association Congress
EHA 2025 | Updated Phase I results of sonrotoclax plus zanubrutinib in R/R CLL/SLL
Chan Cheah, MBBS, FRACP, FRCPA, DMSc, Linear Clinical Research and Sir Charles Gairdner Hospital, Perth, Australia, presents the updated Phase I results of the ongoing BGB-11417-101 trial (NCT04277637) investigating a dual oral BCL2-BTK inhibitor therapy with sonrotoclax and zanubrutinib in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The study demonstrated encouraging safety and efficacy, with the all-oral doublet therapy achieving a 30-month progression-free survival (PFS) rate of 94.7% in a patient population enriched for high-risk characteristics. This interview took place at the 30th Congress of the European Hematology Association (EHA) in Milan, Italy.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.